Z H Siddik
Overview
Explore the profile of Z H Siddik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
104
Citations
1174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Calvert A, Newell D, Gumbrell L, OReilly S, Burnell M, Boxall F, et al.
J Clin Oncol
. 2023 Sep;
41(28):4453-4454.
PMID: 37757592
A dosage formula has been derived from a retrospective analysis of carboplatin pharmacokinetics in 18 patients with pretreatment glomerular filtration rates (GFR) in the range of 33 to 136 mL/min....
2.
Xie X, Lozano G, Siddik Z
Oncogene
. 2016 Feb;
35(36):4798-806.
PMID: 26876197
Cisplatin is an important antitumor agent, but its clinical utility is often limited by multifactorial mechanism of resistance. Loss of tumor suppressor p53 function is a major mechanism that is...
3.
He G, Kuang J, Koomen J, Kobayashi R, Khokhar A, Siddik Z
Br J Cancer
. 2013 Oct;
109(9):2378-88.
PMID: 24104967
Background: In cycling tumour cells, the binary cyclin-dependent kinase Cdk4/cyclin D or Cdk2/cyclin E complex is inhibited by p21 following DNA damage to induce G1 cell-cycle arrest. However, it is...
4.
He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar A, et al.
Br J Cancer
. 2006 Nov;
95(11):1514-24.
PMID: 17088910
The cisplatin analogue 1R,2R-diaminocyclohexane(trans-diacetato)(dichloro)platinum(IV) (DAP) is a DNA-damaging agent that will be entering clinical trials for its potent cytotoxic effects against cisplatin-resistant tumour cells. This cytotoxicity may reside in its...
5.
Verschraegen C, Kumagai S, Davidson R, Feig B, Mansfield P, Lee S, et al.
J Cancer Res Clin Oncol
. 2003 Sep;
129(10):549-55.
PMID: 14513369
Purpose: To perform a phase I study of intraperitoneal cis-bis-neodecanoato ( trans- R, R-1, 2-diaminocyclohexane)-platinum II entrapped in multilamellar vesicles (L-NDDP) for peritoneal carcinomatosis or sarcomatosis. Methods: Eligible patients had...
6.
Kuang J, He G, Huang Z, Khokhar A, Siddik Z
Clin Cancer Res
. 2001 Nov;
7(11):3629-39.
PMID: 11705886
1R,2R-Diaminocyclohexane(trans-diacetato)(dichloro)-platinum(IV) (DACH-acetato-Pt) is a novel platinum-based agent that is highly effective against cisplatin-resistant ovarian tumor cells. To probe its cellular mechanism, the effects of DACH-acetato-Pt (0-6.4 microM) on cell cycle...
7.
Ali Khan S, Huang S, Shamsuddin S, Inutsuka S, Whitmire K, Siddik Z, et al.
Bioorg Med Chem
. 2000 Mar;
8(3):515-21.
PMID: 10732967
A series of new platinum(IV) complexes of the type [PtIV(DACH)trans(L)2Cl2] (where DACH = trans-1R,2R-diaminocyclohexane, and L = acetate, propionate, butyrate, valerate, hexanoate, or heptanoate) bearing the carboxylate groups in the...
8.
Donato N, Perez M, Kang H, Siddik Z, Ling Y, Perez-Soler R
Clin Cancer Res
. 2000 Feb;
6(1):193-202.
PMID: 10656450
Cell cycle regulators and signal transduction pathways can influence apoptotic sensitivity of tumor cells, and we previously described an association between EGFr overexpression, reduced DNA repair activity, and increased apoptotic...
9.
Ali M, Whitmire K, Toyomasu T, Siddik Z, Khokhar A
J Inorg Biochem
. 2000 Jan;
77(3-4):231-8.
PMID: 10643661
A series of new platinum(II) and (IV) complexes with homopiperazine have been synthesized and characterized by elemental analysis, infrared, and 195Pt nuclear magnetic resonance spectroscopic techniques. The complexes are of...
10.
Furui T, Lapushin R, Mao M, Khan H, Watt S, Watt M, et al.
Clin Cancer Res
. 2000 Jan;
5(12):4308-18.
PMID: 10632375
Lysophosphatidic acid (LPA) is one of the major growth factors in ascites from ovarian cancer patients and appears to play an important role in proliferation, survival, and invasion of ovarian...